The US Food and Drug Administration may issue a series of white papers outlining the most up-to-date knowledge on drug/diagnostic codevelopment, a top agency official said at a recent conference.

Since the FDA issued its first white paper on Rx/Dx codevelopment in 2005, the agency's understanding of the issues involved has "significantly increased," said Janet Woodcock, director of FDA's Center for Drug Evaluation and Research, at the "FDA-Industry IVD/Companion Diagnostic Drug Roundtable" in Washington, DC, last month.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.